Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance: a global cross-sectional survey.


Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 31 01 2019
accepted: 05 03 2019
pubmed: 23 3 2019
medline: 15 11 2019
entrez: 23 3 2019
Statut: ppublish

Résumé

To identify differences in perception on multi-drug-resistant (MDR) organisms and their management at intensive care units (ICU). A cross-sectional survey was conducted. A proposal addressing a pathogen priority list (PPL) for ICU, arising from the TOTEM study, was compared with a sample of global experts in infections in critically ill patients. The survey was responded by 129 experts. Globally, ESBL Enterobacteriaceae, followed by carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Klebsiella pneumoniae, were the main concerns. Some differences in opinion were identified between 63 (49%) ICU physicians (ICU/anesthesiology) and 43 (33%) infectious disease consultants (ID physicians/microbiologists). The pathogens most concerning in the ICU for intensivists were ESBL Enterobacteriaceae (38%) versus carbapenem-resistant A. baumannii (48.3%) for ID consultants, (p < 0.05). Increasing number of ID consultants over intensivists (26% vs 14%) reported difficulty in choosing initial therapy for carbapenem-resistant A. baumannii. For intensivists, the urgent measures to limit development of antibiotic resistance were headed by cohort measures (26.3%) versus increasing nurse/patient ratio (32.5%) for ID consultants, (p < 0.05). Regarding effectiveness to prevent MDR development and spread, education programs (42.4%) were the priority for intensivists versus external consultation (35.7%) for ID consultants. Finally, both groups agreed that carbapenem resistance was the most pressing concern (> 70%) regarding emerging resistance. Differences in priorities regarding organisms, infection control practices, and educational priorities were visualized between ID/clinical microbiologists and ICU/anesthesiologists. Multi-disciplinary collaboration is required to achieve best care for ICU patients with severe infections.

Identifiants

pubmed: 30900056
doi: 10.1007/s10096-019-03530-1
pii: 10.1007/s10096-019-03530-1
doi:

Substances chimiques

Anti-Bacterial Agents 0
Carbapenems 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1235-1240

Subventions

Organisme : Wellcome Trust
ID : 205214/Z/16/Z
Pays : United Kingdom

Références

JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
J Antimicrob Chemother. 2011 May;66 Suppl 4:iv43-iv48
pubmed: 21521706
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Clin Infect Dis. 2015 Jul 15;61(2):155-6
pubmed: 25824816
J Infect Dev Ctries. 2015 Oct 29;9(10):1040-5
pubmed: 26517477
Emerg Microbes Infect. 2016 Mar 23;5:e27
pubmed: 27004762
Am J Infect Control. 2016 Nov 1;44(11):1296-1301
pubmed: 27339791
Elife. 2016 Sep 06;5:
pubmed: 27599374
PLoS One. 2016 Oct 24;11(10):e0165242
pubmed: 27776162
J Infect. 2017 Feb;74(2):131-141
pubmed: 27838521
Lancet Infect Dis. 2017 Feb;17(2):153-163
pubmed: 27866944
J Infect Dis. 2017 Feb 15;215(suppl_1):S9-S17
pubmed: 28375515
Intensive Care Med. 2017 Aug;43(8):1164-1166
pubmed: 28409204
Intensive Care Med. 2018 Jan;44(1):79-82
pubmed: 28409205
Infect Control Hosp Epidemiol. 2017 Jul;38(7):848-856
pubmed: 28566096
Semin Respir Crit Care Med. 2017 Jun;38(3):253-263
pubmed: 28578550
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2155-2163
pubmed: 28624864
Clin Infect Dis. 2017 Nov 13;65(11):1921-1923
pubmed: 29020322
Am J Infect Control. 2018 Sep;46(9):1060-1068
pubmed: 29661630
Clin Infect Dis. 2019 Jan 18;68(3):519-524
pubmed: 30020449
Eur J Clin Microbiol Infect Dis. 2019 Feb;38(2):319-323
pubmed: 30426331
JAMA. 1995 Aug 23-30;274(8):639-44
pubmed: 7637145

Auteurs

Jordi Rello (J)

CIBER de Enfermedades Respiratorias, CIBERES, Barcelona, Spain. jrello@crips.es.
Vall d'Hebron Institut of Research (VHIR), Barcelona, Spain. jrello@crips.es.

Vandana Kalwaje Eshwara (V)

Department of Microbiology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.

Andrew Conway-Morris (A)

Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK.

Leonel Lagunes (L)

Intensive Care Department, San Luis Potosi, Mexico.

Joana Alves (J)

Infectious Diseases, Braga Hospital Center, Braga, Portugal.

Emine Alp (E)

Department of Infectious Diseases and Clinical Microbiology, Medical Faculty, Erciyes University, Kayseri, Turkey.

Zhongheng Zhang (Z)

Department of Emergency Medicine, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Mervyn Mer (M)

Department of Medicine, Divisions of Critical Care and Pulmonology, Charlotte Maxeke Johannesburg Academic Hospital and Faculty of Heath Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH